Recently, the Sinopharm Group has been at the forefront of battling the COVID-19 pandemic with its COVID-19 vaccine. Known as the Sinopharm BBIBP-CorV vaccine (or the Sinopharma COVID-19 vaccine), the vaccine has been found to have a 78.1% efficiency against the novel coronavirus. The company has already started its vaccination campaigns in countries across Asia, South America, Africa, and Europe. The group expects to manufacture one billion doses of the COVID-19 vaccine by the end of 2021.
The publisher presents an Analysis of Sinopharm Group. A complete and comprehensive analysis of Sinopharm Group includes an overview of the industry the company operates in and the impact of the COVID-19 pandemic on the pharmaceutical industry.
Company analysis includes a history of Sinopharm, a business segment analysis of the segments Sinopharm operates through, a look at the organization structure of the company, its product pipeline, investment analysis, a geographical operating segments analysis, and how Sinopharm has been working at the forefront during the COVID-19 pandemic are all analyzed comprehensively in this report.
The major competitors of Sinopharm, namely China Resources Sanjiu Medical & Pharmaceutical, Shanghai Pharmaceutical Co. Ltd., and the Tasly Pharmaceutical Group, are analyzed through a company profile, in-depth business segment analysis, a financial analysis, and SWOT analysis. An economic analysis of Sinopharm is also presented through ratio analysis, profit and loss analysis, presentation of the company balance sheet, and much more.
A SWOT Framework Analysis of Sinopharm Group completes this in-depth company analysis.
Table of Contents
A. Executive Summary
B. Looking at the Industry
B.1 Industry Definition
B.2 Brief Profile of the Industry
B.3 Impact of Covid-19 on the Pharmaceutical Industry
B.4 Industry SWOT Analysis
C. Looking at Sinopharm Group
C.1 Company Profile
C.2 History of the Company
C.3 Sinopharm Group and the COVID-19 Pandemic
C.4 Organizational Divisions
C.5 Profiling the Key Executives
C.6 Products & Services
D. Looking at Business
D.1 Business Segments
D.2 Investment Analysis
D.3 Product Pipeline
D.4 Geographical Segments
D.5 Company Subsidiaries
E. Sinopharm Group: SWOT Framework Analysis
E.1 Strengths to Build Upon
E.2 Weaknesses to Overcome
E.3 Opportunities to Exploit
E.4 Threats to Overcome
F. Profiling the Competition
F.1 China Resources Sanjiu Medical & Pharmaceutical Co Ltd
F.1.1 Corporate Profile
F.1.2 Business Segment Analysis
F.1.3 Financial Analysis
F.1.4 SWOT Analysis
F.2 Shanghai Pharmaceutical Co Ltd
F.2.1 Corporate Profile
F.2.2 Business Segment Analysis
F.2.3 Financial Analysis
F.2.4 SWOT Analysis
F.3 Tasly Pharmaceutical Group Co Ltd
F.3.1 Corporate Profile
F.3.2 Business Segment Analysis
F.3.3 Financial Analysis
F.3.4 SWOT Analysis
G. Sinopharm Group: Financial Analysis of the Company
G.1 Current Financials
G.2 Balance Sheet
G.3 Profit & Loss Statement
G.4 Ratio Analysis
H. Sinopharm Group: Outlook
I. Glossary of Terms
Companies Mentioned
- Sinopharma Group
- China Resources Sanjiu Medical & Pharmaceutical Co Ltd
- Shanghai Pharmaceutical Co Ltd
- Tasly Pharmaceutical Group Co Ltd
